HCV/HBV coinfection: The dark side of DAAs treatment?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Direct antiviral agents in hepatitis C virus related liver disease: Don't count the chickens before they're hatched.World journal of gastroenterology · 2021
   Review
2. Hepatitis B Virus (HBV) Reactivation Following Pharmacological Eradication of Hepatitis C Virus (HCV).Viruses · 2019
   Review
3. Significance and Management of Isolated Hepatitis B Core Antibody (Anti-HBc) in HIV and HCV: Strategies in the DAA Era.Current HIV/AIDS reports · 2018
   Review
4. Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C.World journal of gastroenterology · 2017
   Article

Corrections and comments

• Commented on by
  HBV reactivation after HCV eradication: Deja Vu.2017
• Comment on
  HCV Council--critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape.2016

Authors and funding

4 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as